

## Index

---

- 2004 Regulations *see* clinical trials, 2004 Regulations
- acute rejection 17
- AIDS *see* HIV/AIDS
- allotransplants
- acute rejection management 17
  - chronic rejection management 17
  - consent issues, xenotransplantation
    - compared 175
  - and doctors' dual role 161
  - emerging infectious diseases 21
  - as experimental procedure 66
  - HAR management 16
  - microbiological risk of infection 18–19
  - outline consent to surveillance while on
    - waiting list for 218–219
  - parallel research with
    - xenotransplantation 119
  - reasons why xenotransplantation
    - preferable 3, 14
  - recipients with no other hope 89, 92
  - risk of infection, xenotransplantation
    - compared 133–134
- archiving of samples, surveillance of
  - procedures 193–197
- assisted reproductive technologies (ARTs)
  - regulation 105–106
- Australia
- assisted reproductive technologies (ARTs) regulation 107, 117–118
  - consent guidance 160–161
  - counselling guidance 182
  - definition of xenotransplantation 2
  - ethical review of experimental
    - procedures 77
  - gene therapy regulation 112, 113–114, 114–115
  - health tourism guidance 139–140
  - information disclosure guidance 171, 175
  - IVF guidelines 108
- NGOs' guidelines and reports 123, 124
- patient advocate, role of 181
- public consultation 53–54
- surveillance guidance 208
- vulnerable patients treatment guidance
  - 96–97
  - xenotransplant regulation 132–134, 144
- Austria, gene therapy regulation 115
- Baby Fae case 92, 119
- Beck, Ulrich, risk society concept 14
- benefit, definition of 69
- Better Regulation Task Force
  - guidance on xenotransplant regulation 146
  - and harm principle 39
- Blood, Diane, health tourism case 139–140
- blood donations by recipients, surveillance
  - of 200–201
- British Medical Association (BMA)
  - consent guidance 170
  - consent working party 162
  - IVF working group 109
- BSE crisis
  - media's role in 34–35
  - and precautionary principle 39
  - risk communication during 29–35
  - as trans-scientific policy question 32–34
- Canada
- assisted reproductive technologies (ARTs) regulation 107–108
  - counselling guidance 182
  - definition of xenotransplantation 2
  - ethical review of experimental
    - procedures 77
  - gene therapy regulation 114–115
  - human rights guidance 229
  - information disclosure guidance 175–176
  - public consultation 52
  - public health statutes, effectiveness for
    - xenotransplantation regulation 223

Cambridge University Press

978-0-521-19576-8 - Xenotransplantation and Risk: Regulating a Developing Biotechnology

Sara Fovargue

Index

[More information](#)

## 282 Index

- Canada (*cont.*)
  - recipient selection guidance 99
  - surveillance guidance
    - close contacts 195, 201–202
    - consent and compliance 212–213
    - donations of blood, organs, etc. 200–201
    - health workers 196, 202–203
    - human rights 229
    - local level generally 192–193
    - national level 203
    - post-mortems 201
    - recipients 193, 197–198
    - recipients' sexual activity 198–200
    - third parties 214
  - xenotransplant regulation 121–122, 134
- capacity, statutory test 154–155
- chapter summaries 5–12
- China, health tourism 139–140
- chronic rejection 17
- CJD (Creutzfeldt–Jakob disease)
  - continuing loss of life 35
  - as cross-species infection 20
  - PPS as treatment, legality of providing 67–69, 70–73
  - risk communication 29–35
- clinical governance committees (CGCs)
  - approval from 73–74, 79, 93, 174
  - information disclosure guidance 174–175
- clinical trials
  - 2004 Regulations
    - and Declaration of Helsinki 82–83
    - definition of medicinal product 84–85
    - research not under *see* research not under 2004 Regulations
  - authorisation 80, 83–84
  - consent 98, 153, 155–157, 179
  - experimental procedures distinguished 62
  - information disclosure requirements 173–174
  - as legal process for xenotransplantation 83–84, 131, 173–174
  - offers of treatment 94–95
  - statutory regime 62
- close contacts, surveillance of 195–196, 201–202
- Clothier Committee on gene therapy 113–114
- commercial sector
  - health tourism by 140
  - problems with regulation 141–143
- competency for giving consent 150–151, 154–159 *see also* recipients, with no other hope
- compliance
  - consent procedures 211–217
  - effect of measures, level of discussion 211–212
  - methods 217–228
  - specific legislation, need for 217
- confidence, public *see* public involvement
- consent
  - ability to give or obtain 150–151
  - adequacy of 150
  - allotransplantation issues,
    - xenotransplantation compared 175
  - appropriateness of 149–150
  - capacity, statutory test 154–155
  - changes in procedure 179–183
  - competency 150–151, 154–159
    - see also* recipients, with no other hope
  - and compliance 212–214, 217–228, 241
  - contract law consent to surveillance 218–220
  - counselling 182–183
  - effect of measures, level of discussion 211–212
  - existing procedures, challenges to 9–10
  - importance 148
  - independent person, role of 181
  - individual's right to give, balance with public safety 151–154
  - informed decision-making 166–179
    - see also* information disclosure
  - legal framework 150–154
  - main issues 150
  - patient advocate, role of 181–182
  - permissibility of 149
  - requirements for valid consent 154–179
  - summary of issues 185–188
  - to surveillance 206–207, 211–217, 218–220
  - third parties *see* third-party consent
  - voluntariness
    - dual role of doctor 160
    - issues affecting 159–160
    - process of obtaining consent 160
  - withdrawal of 216–217
- contacts *see* close contacts
- contract law
  - compliance via 218–220
  - 'Ulysses Contract' 219
- cost-benefit analysis, use of 36–37
- Council for International Organisations of Medical Sciences (CIOMS)
  - experimental procedures guidance 76
  - guidance on risk evaluation 82
  - information disclosure guidance 169

Cambridge University Press

978-0-521-19576-8 - Xenotransplantation and Risk: Regulating a Developing Biotechnology

Sara Fovargue

Index

[More information](#)

## Index

283

- vulnerable patients treatment guidance 93, 95–96
- Council of Europe
  - compliance guidance 232
  - consent guidance 154
  - counselling guidance 182
  - definition of xenotransplantation 2, 66
  - gene therapy regulation 115–116
  - human rights guidance 229
  - information disclosure guidance 175, 187
  - and precautionary principle 40–41
  - recipient selection guidance 93–94
  - recommendations on
    - xenotransplantation outside research 77, 83–84
  - surveillance guidance 209, 213, 214, 215
  - third-party consent guidance 184
  - vulnerable patients treatment guidance 98
  - xenotransplant guidance 126–127
- Council of Science and Society, IVF report 109
- criminal law, compliance via 223
- decision-making process
  - see also* information disclosure
  - decision-making categories 23–24, 36
  - doctors' role 155–156
  - importance 148
  - precautionary principle 48–49, 58
  - public involvement in 47–57
- Declaration of Helsinki
  - compliance with 80, 148
  - consent guidance 153, 155, 181
  - doctors' role, guidance on 160
  - enactment into law 82–83, 142
  - experimental procedures guidance 76
  - information disclosure guidance 168–169
  - principles for medical research combined with medical care 81–82
  - recipient selection guidance 97
  - requirement for informed consent 93
  - vulnerable patients treatment guidance 95
- Department of Health (DH)
  - committee on biotechnology 120
  - consent guidance 148
  - definition of medicinal product 84, 85
  - disregard of guidance from 87
  - information disclosure guidance 169, 172, 179
  - public consultation 51–52
  - UKXIRA abolition 129–130
- vulnerable patients treatment guidance 98
- xenotransplant guidance 79, 83, 86, 131
- disclosure of information *see* information disclosure
- doctors *see also* health workers
  - aim in using experimental procedure 63–64
  - discretion to offer procedure 62–63, 75, 77, 79, 92–93, 100–102
  - see also* recipients,
- doctor–patient relationship
  - and compliance 217
  - and contract law 219
  - in medical research 64–65
  - obtaining consent 163–166
  - patients with no other hope 155–157
- dual role 97, 101, 160
- duty to provide information 187
- information disclosure by 167–168
- informed decision-making, role in 155–156
- option to comply with regulatory scheme 78
- and patient advocates 181–182
- perception of risk, contrast with recipient 26
- surveillance and monitoring role 197–198, 201
- donor organs *see* organ donations
- Ebola, as cross-species infection 20
- enforcement
  - issue of 190–191, 199–200, 206–207
  - level of discussion as to effect 211–212
  - powers in new legislation 228
  - of surveillance contract 219–220
- ethical guidance
  - experimental procedures 76–77
  - medical research 81–83
  - offers of experimental procedures 93
  - offers of medical research 95–97
- ethical norms
  - challenges to, main issues 150
  - as theme of book 9–10
- European Centre for Disease Prevention and Control
  - role of 210
  - website 210
- European Commission, and precautionary principle 39
- European Convention on Human Rights (ECHR)
  - individual's rights to health 44
  - public health powers compliance 43–44
  - and surveillance regimes 229–232

Cambridge University Press

978-0-521-19576-8 - Xenotransplantation and Risk: Regulating a Developing Biotechnology

Sara Fovargue

Index

[More information](#)

## 284 Index

- European Convention on Human Rights and Biomedicine, information disclosure guidance 168
- European Union
  - assisted reproductive technologies (ARTs) regulation 110
  - definition of medicinal product 84
  - gene therapy regulation 115–116
- experimental procedures
  - allotransplants classified as 66
  - clinical trials distinguished 62
  - doctors' aim in using 63–64
  - doctors' decision to offer 75, 77, 79, 92–93, 100–102 *see also* recipients, selection procedures
  - ethical guidance 76–77
  - focus on individual patient 62–64
  - information disclosure requirements 174
  - interests involved 61
  - law as to 70–75
  - legal definitions as to 62–64
  - as legal process for xenotransplantation 79, 83–84, 131, 174
  - and medical research, distinction 64–65, 70–73
  - offers of *see* offers of experimental procedures
  - 'one-off' procedures, legality 70–73
  - outside clinical trials framework, legality 73–74
  - regulatory schemes 70–79
  - review 73–74, 77
  - and xenotransplantation 78–79
- Expert Scientific Group, review of TGN1412 drug trial 186
- Feinberg, Joel, notions of harm 40
- first-party consent *see* consent
- France
  - assisted reproductive technologies (ARTs) regulation 107
  - definition of xenotransplantation 2
  - gene therapy regulation 113–114, 115
  - information disclosure guidance 175
  - xenotransplant regulation 121, 135
- gene therapy
  - public involvement in decisions as to 51
  - regulation
    - emerging themes 117–119
    - government committee recommendations 113–114
    - international regulation 115–116
    - NGOs' guidelines and reports 114–115
    - post-clinical 1990–2000 113–115
    - pre-clinical 111–113
    - statutory regulation 115
- Gene Therapy Advisory Committee (GTAC)
  - consent guidance, compliance with 173–174
  - counselling guidance 182
  - establishment 113–114
  - ethical review by 83–84, 86
  - information disclosure guidance 173, 187
  - rejection of proposed procedure 174
- General Medical Council (GMC)
  - consent guidance 153, 165–166, 169–170
  - definition of medicinal product 85
  - experimental procedures guidance 77
  - information disclosure guidance 179
  - vulnerable patients treatment guidance 96
- genetically engineered solid organ xenotransplants, legal definitions 65–70
- Germany
  - gene therapy regulation 112, 115
  - xenotransplant regulation 121, 136
- global issues
  - global regulation 143
  - global risks as theme of book 10–11
  - problems with regulation 138–140
- Glover Report on new reproductive technologies 112
- GM crops
  - public involvement in decisions as to 49–50
  - public suspicion of 29
- harm principle
  - application of 39–40, 45, 235, 238
  - Feinberg's notions of harm 40
  - and precautionary principle 15, 39, 57–58, 185, 231
  - prevention of harm, issue of 4–5
  - public health measures and 43–44
  - and risk 23
  - and xenotransplantation 40–42
- health tourism
  - discussions on 209
  - problems with regulation 138–140

Cambridge University Press

978-0-521-19576-8 - Xenotransplantation and Risk: Regulating a Developing Biotechnology

Sara Fovargue

Index

[More information](#)

## Index

285

- health workers *see also* doctors
  - occupational health service (OHS), access to 196–197
  - surveillance of 196–197, 202–203
- HIV/AIDS
  - as cross-species infection 20
  - deliberate infection with, criminal law sanctions 223
  - latent effect 18
  - retroviral action 20
- Hong Kong, SARS epidemic 34
- Human Fertilisation and Embryology Authority, establishment 107
- human rights *see also* individual, rights of
  - compliance of new legislation with 226
  - consideration of 191
  - limitation of 240–241
  - Siracusa Principles, applicability of 232
  - and surveillance 228
  - as theme of book 11–12
- Human T cell Lymphotropic Virus, as cross-species infection 20
- hyperacute rejection (HAR) 16
- ICH guidelines
  - experimental procedures guidance 82
  - information disclosure guidance 169
  - vulnerable patients treatment guidance 96
- immunological barriers 16–17
- India, health tourism 139–140
- individual patient *see also* recipients
  - consent *see* consent
  - focus of experimental procedures on 62–64
  - and harm principle 39–40, 41–42
  - imposition of risks on other persons, permissibility 90
  - perception of risk
    - changes in 26
    - contrast with health professionals 26
  - rights of
    - infringement of, prohibition of xenotransplantation as 46–47
  - interaction with public health 4–5, 6, 9, 15, 44, 151–154, 238
    - see also* surveillance and monitoring
  - prioritisation of 238–239
  - respect for 11–12
  - relationship with doctor *see* doctors
- infections
  - control methods 189
  - from pig organs *see* PERVs; pig organs
  - risk, allotransplants and xenotransplants compared 133–134
  - transmission of
    - across species, examples 20
    - potential for 21–23
    - risk evaluation 19–21
- influenza
  - as cross-species infection 20
  - speed of response to epidemics 210–211
- information disclosure
  - content of disclosure 168–172
  - decision to disclose 167–168
  - information overload, problem of 178–179
  - plain English, use of 166
  - to recipients 172–177
  - standards for 166–179
- informed consent *see* consent; decision-making process
- innovative practice, legal definitions of 62–64
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) *see* ICH guidelines
- International Covenant on Civil and Political Rights, departure from 232
- International Society for Heart and Lung Transplantation, xenotransplantation recommendations 123–124
- International Xenotransplantation Association (IXA)
  - on importance of public involvement 54
  - surveillance guidance 213
  - on withdrawal of consent 217
  - on xenotransplantation monitoring 23
- investigator, doctors' dual role 97, 101, 160
- Ireland, 'significant risk' defined in case law 167
- Italy, IVF code of practice 109
- IVF, regulation of
  - consent schemes, statutory regulation 187
  - emerging themes 117–119
  - government committee recommendations 107–108
  - international regulation 110
  - NGOs' guidelines and reports 108–109
  - post-clinical 1978–1988 107–110
  - pre-clinical 104–106
  - recommendations by World Congress 110
  - statutory regulation 109

Cambridge University Press

978-0-521-19576-8 - Xenotransplantation and Risk: Regulating a Developing Biotechnology

Sara Fovargue

Index

[More information](#)

## 286 Index

- Japan, gene therapy regulation 114–115
- known infections, transmission of, risk evaluation 19–21
- legal definitions as to medical research 62–70
- legal norms
  - challenges to, main issues 150
  - as theme of book 9–10
- legislation *see* regulation
- Louise Brown, birth of, regulatory response 106, 107–108
- media
  - and BSE crisis 34–35
  - risk communication 26–28
  - and SARS epidemic 34
- medical research *see also* clinical trials; experimental procedures
  - doctor–patient relationship 64–65
  - ethical guidance 81–83
  - and experimental procedures, distinction 64–65, 70–73
  - form of statutory regime 62
  - interests involved 61
  - law as to 80
  - legal definitions as to 62–70
  - offers of *see* offers of medical research
  - regulatory schemes 80–87
  - and xenotransplantation 83–87
- Medical Research Council (MRC)
  - ethical review of experimental procedures 105
  - IVF working group 105, 108
- medicinal product, legal definitions 84–86
- Medicines and Healthcare Products Regulation Agency (MHRA)
  - authorisation of clinical trials 80, 83–84
  - definition of medicinal product 85
- Mexico, health tourism 139–140
- microbiological barriers 18–19
- Mill, John Stuart *see* harm principle
- monitoring *see* surveillance and monitoring
- National Expert Panel on New and Emerging Infections (NEPNEI), and xeno-tourism issue 209
- National Institute for Health and Clinical Excellence (NICE)
  - effectiveness of guidance 102
  - experimental procedures guidance 93
  - information disclosure guidance 170, 174
  - notification to 174
  - review of experimental procedures 73–74
- National Research Ethics Service (NRES)
  - consent guidance, compliance with 173–174
  - information disclosure guidance 169, 187
  - rejection of proposed procedure 174
  - review by 83–84
- Netherlands
  - assisted reproductive technologies (ARTs) regulation 107
  - gene therapy regulation 112, 113–114, 115
  - information disclosure guidance 175
  - IVF regulation 109
  - surveillance guidance 198, 215
  - third-party consent guidance 184–185
  - xenotransplant regulation 121, 135–136
- new variant CJD *see* CJD
- New Zealand
  - consent, independent person's role in procedure 181
  - definition of xenotransplantation 2
  - ethical review of experimental procedures 77
  - information disclosure guidance 171, 175, 187
  - innovative practice, definition 63–64
  - NGOs' guidelines and reports 123
  - review of experimental procedures 74
  - surveillance guidance 208–209
  - vulnerable patients treatment guidance 97
  - xenotransplant regulation 122, 125, 134–135
- Nipah virus, potential for infection 21
- Norway
  - IVF regulation 109
  - surveillance guidance 208
  - xenotransplant regulation 120–121
- Nuffield Council on Bioethics
  - consultation on xenotransplantation 123
  - definition of xenotransplantation 65–66
  - disregard of guidance from 87
  - guidance on treatment of patients with no other hope 91
  - human rights guidance 235
  - information disclosure report 177, 178
  - and precautionary principle 41
  - public consultation 51
  - risk management guidance 36
- occupational health service (OHS), access to 196–197

Cambridge University Press

978-0-521-19576-8 - Xenotransplantation and Risk: Regulating a Developing Biotechnology

Sara Fovargue

Index

[More information](#)

## Index

287

- offers of experimental procedures
  - ethical guidance 93
  - law as to 92
  - regulation of 92–94
  - xenotransplantation 93–94
- offers of medical research
  - ethical guidance 95–97
  - law as to 94–95
  - regulation of 94–99
  - and xenotransplantation 98–99
- ‘one-off’ procedures, legality of 70–73
- organ donations
  - pig organs *see* pig organs
  - by recipients, surveillance of 200–201
  - shortage of, xenotransplantation as viable solution 5, 14
- organ rejection, types of 16
- Organization for Economic Co-operation and Development (OECD)
  - surveillance guidance 205, 210, 213
  - ‘Ulysses contract’ 219
  - xenotransplant guidance 125–126
- patient *see* individual patient
- patient advocate, role of 181–182
- pentosan polysulphate (PPS), legality of providing 67–69, 70–73
- PERVs
  - action of 19–20
  - effects of 20
  - infection from 19–21
  - listing as notifiable disease 210
  - potential for infection 21–23
- physiological barriers 17–18
- pig organs
  - infection from *see also* PERVs
  - microbiological risks 18–19
  - unknown viruses 21
  - physiological differences to human organs 17–18
  - rejection 16–19
  - as source of xeno-organs 16
- Plain English Campaign, role in drafting patient information 166
- Pontifical Academy for Life, recommendations on xenotransplantation 123
- porcine endogenous retroviruses *see* PERVs
- post-mortems of recipients, surveillance regimes 200–201
- precautionary principle
  - application of 37–39, 238
  - clinical trials 57
  - and decision-making 48–49, 58
  - and harm principle 15, 39, 57–58, 185, 231
- SARS epidemic 232
- and xenotransplantation 40–42, 154, 231, 232
- prohibition of developing technology
  - as infringement of recipients’ autonomy 46–47
  - precedent for 45–46
- public health issues
  - aspects relevant to xenotransplantation 15
  - characteristics of public health measures 43–44
  - developments in approach to 43–45
  - interaction with individual patient’s rights 4–5, 6, 9, 15, 44, 151–154
  - prioritisation of needs 238–239
  - as theme of book 10–11
  - and xenotransplantation 45–47
- public health law, compliance via 220–223
- public health measures
  - and harm principle 43–44
  - justificatory conditions 190
- public involvement
  - BSE crisis 29–35
  - in consultation on xenotransplantation 51–54
  - in decision-making process 47–57
  - gap between expert and public perceptions of risk 26
- GM crops 29
- increase in consultation 7
- and individual’s right to give consent 151–154
- need for consultation 6–7, 239–240
- and risk communication 25–26
- as theme of book 6–7
- trust and confidence issues as to risk 28–29
- understanding of science issues, need for 14
- ‘Xeno Nation’ debate 55–56
- in xenotransplant decisions 54–57
- recipients *see also* individual patient
  - close contacts, surveillance of 195–196, 201–202
  - consent, obtaining *see* consent
  - existing protection, whether sufficient 4–5
  - information disclosure to 172–177
  - infringement of autonomy of 46–47
  - perception of risk, contrast with health professionals 26

Cambridge University Press

978-0-521-19576-8 - Xenotransplantation and Risk: Regulating a Developing Biotechnology

Sara Fovargue

Index

[More information](#)

## 288 Index

- recipients (*cont.*)
  - with no other hope
    - allotransplants 89, 92
    - benefit to, definition of 69
    - competency for giving consent 155–157, 166, 177–178
    - competency status 157–159
    - ethical guidance as to 93, 96–97
    - health status 75, 77
    - obtaining consent from, approach to 180–181, 241
    - selection of 61–62, 88–92, 97, 98–99
    - vulnerable patients, definition of 93
  - selection procedures
    - regulation generally 87–92
    - xenotransplantation 90–92
  - surveillance of
    - donations of blood, organs, etc. 200–201
    - post-mortems 200–201
    - sample storage 200–201
    - sampling 193–195
    - sexual activity 198–200
    - vulnerable patients, definition of 93
- regulation *see also* compliance; enforcement; legal norms; surveillance and monitoring
  - approaches to devising 117–119, 243–246
  - of consent *see* consent
  - doctors' option to follow 78
  - existing protection, whether sufficient 4–5
  - forms of 61
  - gene therapy *see* gene therapy
  - global issues *see* global issues
  - and human rights *see* human rights
  - IVF *see* IVF, regulation of
  - legal definitions as to medical research 62–70
  - main issues 61–62, 103–104
  - new legislation, introduction 226–228
  - of offers of experimental procedures 92–94
  - of offers of medical research 94–99
  - problems with regulation 103–104, 138–143
  - regulatory schemes 70–87
  - review and recommendations for reform 80
  - of selection procedures 87–92
  - strengthening of 242–243
  - summary of issues 99–102, 144–147
  - as theme of book 7–8
  - xenotransplantation
    - compliance via introduction of specific legislation 226–228
    - development of regulation 119–127
    - government committee recommendations 120–122
    - implementation legislation 135–137
    - implementation of recommendations 127–138
    - international implementing legislation 137–138
    - international regulation 125–127
    - national committees 128–135
    - NGOs' guidelines and reports 123–124
    - pre-clinical 119–125
    - statutory regulation 124–125
  - rejection of organs *see* organ rejection
  - reproductive cloning, prohibition of 45–46
  - research ethics committees (RECs)
    - approval from 76, 79, 80, 81, 82, 94, 97
    - consent guidance 164
    - problems with 87
    - review by 73, 77, 81, 83–84, 86, 96, 98–99, 100
    - role of 130–131
  - research not under 2004 Regulations
    - consent 179
    - information disclosure requirements 174
    - as legal process for xenotransplantation 83–84, 131, 174
  - retroviruses *see* PERVs
  - risk *see also* global issues
    - assessment 19–42
    - balance with benefits 14, 45, 66–69
    - communication
      - complexity of issues 24–25
      - gap between expert and public perceptions 26
      - by media 26–28
      - public understanding of 25–26
    - concept of 23–24
    - decision-making categories 23–24, 36
    - evaluation 19–23
    - and harm 23
    - main issues 14–16
    - management 35–42, 238–240
      - see also* cost–benefit analysis; harm principle; precautionary principle
    - management principles 35–36
    - manufactured risk, xenotransplantation as 24
    - need to address 237–238, 245
    - perception of *see* individual patient and public health issues 43–47
    - and public involvement 47–57
    - regulation of, xenotransplantation as example of 4



- risk society concept (Beck) 14
- significant risk, definition 167
- summary of issues 57–60
- technological risks, characteristics of 24
- as theme of book 5–6
- trust and confidence issues 28–29
- Royal College of Obstetricians and Gynaecologists (RCOG), IVF guidelines 109
- Royal College of Physicians (RCP)
  - ethical review of experimental procedures 77
  - information disclosure guidance 169, 170
  - innovative practice guidance 64
  - vulnerable patients treatment guidance 96
- samples
  - storage, surveillance of procedures 193–197
  - taking of, surveillance of procedures 200–201
- SARS epidemic
  - ability to monitor 189–190
  - media–government relationship 34
  - and precautionary principle 232
  - responses to 228
  - speed of response 210–211
- selection of recipients *see* recipients
- Sense About Science
  - establishment of 26
  - report on presentation of treatment claims 157
- sexual activity of recipients, surveillance of 198–200
- significant risk, definition 167
- Siracusa Principles, applicability 232
- Spain
  - assisted reproductive technologies (ARTs) regulation 107
  - IVF regulation 109
  - xenotransplant regulation 121, 128
- Strategy Unit, risk management principles 35–36
- surveillance and monitoring
  - see also* enforcement
  - of archiving procedures 193–197
  - of close contacts 195–196, 201–202
  - compliance methods 217–228
  - consent to 206–207, 211–217, 218–220
  - doctors' role 197–198, 201, 217
  - and ECHR 229–232
  - effectiveness 205–208
  - of health workers 196–197, 202–203
  - and human rights 228
  - international collaboration, need for 190–191
  - international level 204–205
  - local level 192–203
  - main issues 189–191
  - national level 203–204
  - need for 189
  - post-2000 regimes 208–211
  - pre-2000 proposed regimes 191–205
  - publication of guidance 41, 191–192
  - of recipients 193–195, 197–201
    - see also* recipients
  - of sampling procedures 193–197
  - strengthening of 241–242
  - summary of issues 233–236
  - surveillance contract, enforcement 219–220
- Sweden
  - consent, independent person's role in procedure 181
  - definition of xenotransplantation 2
  - gene therapy regulation 113–114
  - information disclosure guidance 175
  - IVF regulation 109
  - public consultation 53
  - vulnerable patients treatment guidance 99
  - xenotransplant regulation 120–121
- swine flu
  - as cross-species infection 20
  - as pandemic 154
- swine hepatitis E virus, potential for infection 21
- Switzerland
  - definition of xenotransplantation 2
  - direct democracy 47
  - IVF regulation 109
  - xenotransplant regulation 121, 136–137
- technological imperative 4, 12–13, 44–45
- TGN1412 drug trial, suspension of 186
- therapeutic research, definition of 65–66
- third-party consent
  - compliance 214–216
  - need for 150
  - procedure 183–185

Cambridge University Press

978-0-521-19576-8 - Xenotransplantation and Risk: Regulating a Developing Biotechnology

Sara Fovargue

Index

[More information](#)

## 290 Index

- transmission of infections
  - potential for 21–23
  - risk evaluation 19–21
- transplant activity in UK 2
- Transplantation Society, Ethics Committee
  - guidelines 123, 124
- trust, public *see* public involvement
- ‘Ulysses contract’ 219
- UNESCO, declaration on the human genome 116
- United Kingdom Xenotransplantation Interim Regulatory Authority (UKXIRA)
  - abolition 87, 100, 129–130, 173, 192
  - consent guidance 151, 165
  - definition of therapeutic research 93–94
  - establishment 41, 144–145
  - guidance on xenotransplantation outside research 79
  - human rights guidance 230
  - information disclosure guidance 172–173
  - patient advocate, role of 181
  - publication of report 228–229
  - purpose 86
  - recipient selection guidance 98–99
  - surveillance guidance
    - close contacts 195–196, 201–202, 207
    - consent and compliance 212–213
    - donations of blood, organs, etc. 200–201
    - effectiveness 205
    - health workers 196, 202–203
    - human rights 230
    - local level generally 192–193
    - national level 203–204
    - post-mortems 201
    - publication 41, 192
    - recipients 193–194, 197–198, 209
    - recipients’ sexual activity 198–200
    - third parties 215, 216
    - tissue storage 201
    - withdrawal of consent 216–217
  - validity of guidance post-abolition 192
  - vulnerable patients treatment guidance 98
  - work 128–130
  - and xeno-tourism issue 209
- United States
  - assisted reproductive technologies (ARTs) regulation 105–106
  - Baby Fae case 92, 119
  - concerns as to research 105
  - counselling guidance 182
  - definition of xenotransplantation 2
  - experimental procedures, guidance 70, 100
  - gene therapy regulation 111–113, 115
  - guidance on treatment of patients with no other hope 90
  - health tourism guidance 139–140
  - human rights guidance 229
  - industry guidance 141
  - information disclosure guidance 170–171, 176–177, 178
  - IVF guidelines 109
  - IVF regulation 109
  - Model State Emergency Health Plan Act 227
  - NGOs’ guidelines and reports 123
  - patient advocate, role of 181
  - public consultation 55
  - public health statutes, effectiveness for xenotransplantation regulation 223
  - surveillance guidance
    - close contacts 195, 201–202
    - consent and compliance 212–213
    - donations of blood, organs, etc. 200–201
    - health workers 196–197, 202–203
    - human rights 229
    - local level generally 192–193
    - national level 203
    - post-mortems 201
    - publication 192
    - recipients 194–195, 197–198
    - recipients’ sexual activity 198–200
    - third parties 214, 215
  - vulnerable patients treatment guidance 99
  - xenotransplant regulation 124–125, 131–132
- unknown infections, transmission of, risk evaluation 21
- vCJD *see* CJD
- vulnerable patients, definition 93
  - see also* recipients with no other hope
- Warnock Committee, report 107
- websites
  - European Centre for Disease Prevention and Control 210
  - WHO xenotransplantation inventory 209
- World Congress on IVF, recommendations 110

World Health Assembly (WHA), xenotransplant guidance 125–126	xenotransplantation
World Health Organization (WHO)	barriers to successful transplant 3–4, 16–19
counselling guidance 182	consent <i>see</i> consent
definition of xenotransplantation 2	definitions 1–2
experimental procedures guidance 66, 76, 100	and ethical norms <i>see</i> ethical norms
guidance on risk evaluation 82	focus on 4–5
human rights guidance 229	and human rights <i>see</i> human rights
information disclosure guidance 169	and individual rights <i>see</i> individual, rights of
International Health Regulations 211	legal methods for performing 83–84, 173–175
principles on xenotransplants, UK	and legal norms <i>see</i> legal norms
compliance with 83–84	potential benefits 3
surveillance guidance 205, 206, 210, 242	process of 1–4
‘Ulysses contract’ 219	public health issues <i>see</i> public health issues
vulnerable patients treatment guidance 93, 95–96, 98	public involvement <i>see</i> public involvement
xenotransplant guidance 125–126, 137–138	purpose of book 1, 12–13
xenotransplantation inventory website 209	recipients <i>see</i> recipients
	regulation of <i>see</i> regulation
	results to date 15
	risks from <i>see</i> global issues; risk
	science of 16–19
	summary of issues 237–246
	technological imperative 4, 12–13
	themes of book 5–12
	as viable solution to donor shortage 5
‘Xeno Nation’ debate 55–56	
xeno-recipients <i>see</i> recipients	
xeno-tourism	
discussions on 209	
problems with regulation 138–140	